Cargando…

Decreased blood-brain barrier P-glycoprotein function with aging

Detalles Bibliográficos
Autores principales:	Bauer, Martin, Karch, Rudolf, Abrahim, Aiman, Wagner, Claudia C, Kletter, Kurt, Müller, Markus, Langer, Oliver
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3313239/ http://dx.doi.org/10.1186/1471-2210-8-S1-A48

Ejemplares similares

A combined accelerator mass spectrometry/positron emission tomography microdose study to assess the plasma and brain tissue pharmacokinetics of (11)C- and (14)C-labelled verapamil in healthy volunteers
por: Wagner, Claudia C, et al.
Publicado: (2008)

Dose-response assessment of tariquidar for inhibition of P-glycoprotein at the human blood-brain barrier using (R)-[(11)C]verapamil PET
por: Bauer, Martin, et al.
Publicado: (2010)

A PET microdosing study with the P-glycoprotein inhibitor tariquidar
por: Bauer, Martin, et al.
Publicado: (2012)

[(11)C]Elacridar as a novel P-glycoprotein PET tracer, assessment of whole-body distribution and radiation dosimetry in humans
por: Bauer, Martin, et al.
Publicado: (2011)

Inhibition of breast cancer resistance protein at the murine blood-brain barrier by Ko143 studied with [(11)C]tariquidar and PET
por: Wanek, Thomas, et al.
Publicado: (2011)

Approaching complete inhibition of P-glycoprotein at the human blood–brain barrier: an (R)-[(11)C]verapamil PET study
por: Bauer, Martin, et al.
Publicado: (2015)

Small-animal PET evaluation of [(11)C]MC113 as a PET tracer for P-glycoprotein
por: Mairinger, Severin, et al.
Publicado: (2010)

Pharmacokinetic modeling of P-glycoprotein function at the rat and human blood–brain barriers studied with (R)-[(11)C]verapamil positron emission tomography
por: Müllauer, Julia, et al.
Publicado: (2012)

Imaging P‐Glycoprotein Function at the Blood–Brain Barrier as a Determinant of the Variability in Response to Central Nervous System Drugs
por: Bauer, Martin, et al.
Publicado: (2019)

Factors Governing P-Glycoprotein-Mediated Drug–Drug Interactions at the Blood–Brain Barrier Measured with Positron Emission Tomography
por: Wanek, Thomas, et al.
Publicado: (2015)

Penetration of polar organic compounds through the blood-brain barrier
por: Kalász, Huba, et al.
Publicado: (2011)

(R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood–brain barrier, and not by MRP1 and BCRP
por: Römermann, Kerstin, et al.
Publicado: (2013)

Abstracts from the Virtual Symposium “Signal Transduction at the Blood–Brain Barriers”
Publicado: (2021)

In vivo P-glycoprotein function before and after epilepsy surgery
por: Bauer, Martin, et al.
Publicado: (2014)

EHMTI-0021. The possible effect of telmisartan on the blood-brain barrier transport of verapamil
por: Saaby, PL, et al.
Publicado: (2014)

Abstracts from the International Symposium “Signal Transduction at the Blood–Brain Barriers” 2022
Publicado: (2023)

Abstracts from the 20th International Symposium on Signal Transduction at the Blood-Brain Barriers
por: Małecki, Andrzej, et al.
Publicado: (2017)

Abstracts from the 22nd International Symposium on Signal Transduction at the Blood–Brain Barriers
Publicado: (2019)

BEZ235 impairs gastric cancer growth by inhibition of PI3K/mTOR in vitro and in vivo
por: Füreder, Thorsten, et al.
Publicado: (2010)

Conformation of membrane-inserted P-glycoprotein
por: Stockner, Thomas, et al.
Publicado: (2010)

EHMTI-0125. Studying the permeability of the blood-brain barrier during migraine attacks using [11C]-dihydroergotamine
por: Schankin, C, et al.
Publicado: (2014)

Decrease of red blood cell sialic acid membrane content in septic patients
por: Zouaoui Boudjeltia, K, et al.
Publicado: (2000)

Lung recruitment manoeuvres decrease gastric mucosal blood flow in ICU patients
por: Claesson, SJ, et al.
Publicado: (2002)

Heterogeneous penetration of cefpirome and moxifloxacin into abscesses after simultaneous administration in humans
por: Sauermann, Robert, et al.
Publicado: (2010)

Glucocorticoids cause VE-cadherin upregulation and cytoskeletal rearrangements in the blood-brain barrier endothelial cEND cell line
por: Blecharz, KG, et al.
Publicado: (2009)

Decreased beating rate variability of cultured cardiomyocytes by endotoxin
por: Schmidt, H, et al.
Publicado: (1999)

The effect of a decrease in arterial blood pressure on renal urodilatin excretion in anesthetized rats
por: Heringlake, M, et al.
Publicado: (2003)

High-affinity antibodies against β(2)-glycoprotein I
por: Cucnik, S, et al.
Publicado: (2003)

Factors That Limit Positron Emission Tomography Imaging of P-Glycoprotein Density at the Blood–Brain Barrier
por: Kannan, Pavitra, et al.
Publicado: (2013)

Decreased blood–brain barrier P-glycoprotein function in the progression of Parkinson’s disease, PSP and MSA
por: Bartels, A. L., et al.
Publicado: (2008)

Reactive oxygen species (ROS) generated in vitro decreases human small intestinal muscle contractions and inhibitory neuromuscular transmission
por: Schwarz, NT, et al.
Publicado: (2001)

Human cartilage glycoprotein 39-directed T cell responses in health and arthritic diseases
por: Bilsen, JHM van, et al.
Publicado: (2004)

Impaired in vitro thrombin generation in β2-glycoprotein I null mice
por: Sheng, Y, et al.
Publicado: (2001)

High incidence of decreased cortisol reserve in brain-dead potential organ-donors
por: Dimopoulou, I, et al.
Publicado: (2002)

Characterization of binding interactions in solution between β-2-glycoprotein I and monoclonal antibodies
por: Heegaard, NHH, et al.
Publicado: (2002)

Which conformation does the ABC transporter P-glycoprotein adopt in the physiological membrane environment?
por: Stockner, Thomas, et al.
Publicado: (2012)

Antibodies to beta(2)-glycoprotein I, prothrombin and antithrombin III as markers of the antiphospholipid syndrome severity
por: Zabek, J, et al.
Publicado: (2001)

In vitro and in vivo profiling of P-glycoprotein in human neuroblastoma and rhabdomyosarcoma cells under simvastatin exposure
por: Sieczkowski, Evelyn, et al.
Publicado: (2009)

A prospective analysis of complications related to the use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
por: Rocha, RM, et al.
Publicado: (2001)

Heterogeneous behaviour of anti-beta(2)-glycoprotein I antibodies on different "high binding" microtiter plates
por: Ambrozic, A, et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_dac8fruqev4s8f6685vlv1m45r